Merck Sues To Stop Manufacture Of Generic Fosamax

Law360, New York (April 11, 2006, 12:00 AM EDT) -- In a move to protect its embattled market share for osteoporosis treatments, Merck and Co. Inc. has filed a lawsuit in federal court against Canadian generic drug manufacturer Apotex Inc. to stifle its generic version of Fosamax.

In the lawsuit, filed in U.S. District Court in Delaware, Merck accused Apotex of knowingly infringing nine of its patents for the drug and mirrors a number of other suits that ended last year with a decade being taken of the life of the patent.

The seeds for Merck’s...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.